Published in Clinical Oncology Week, August 25th, 2003
"Although prostate specific antigen (PSA) is widely used in the discrimination of benign prostatic hyperplasia (BPH) and prostate cancer, its diagnostic value is controversial due to an appreciable false positive rate," scientists in Turkey report.
"In the present study, we compared a recently introduced assay method, equimolar PSA measurement, to nonequimolar PSA measurement and also determined the diagnostic value of percent free PSA with changing total PSA (tPSA) measurements," wrote R. Onur and colleagues, University of Firat, Firat Medical Center.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.